FOCUS Hip Fracture Transfusion Trial: Delirium and Other Cognitive Outcomes

FOCUS 髋部骨折输血试验：谵妄和其他认知结果

• 批准号: 7766220
• 负责人: ANN L GRUBER-BALDINI
• 金额: $ 37.95万
• 依托单位: UNIVERSITY OF MARYLAND BALTIMORE
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-02-12 至 2014-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7766220
• 关键词: Academic Medical Centers; Acute; Admission activity; Affect; Age; Ancillary Study; Anemia; Attention; Baltimore; Blood; Blood Transfusion; Boston; Brain; British Columbia; Canada; Cardiovascular Diseases; Cardiovascular system; Cessation of life; Clinic; Clinical Trials; Cognitive; Confusion; Conscious; Day Surgery; Delirium; Dentistry; Disease; Education; Elderly; Equation; Foundations; Fracture; Funding; Future; Health Sciences; Hemoglobin; Hemoglobin concentration result; Hemorrhage; Hip Fractures; Hospitalization; Hospitals; Human; Intention; Intervention; Israel; Lead; Life; Location; London; Lower Extremity; Maryland; Measurement; Measures; Medical center; Medicine; Memory impairment; Metric; Morbidity - disease rate; National Heart, Lung, and Blood Institute; New Brunswick; New Jersey; New York; Nursing Homes; Operative Surgical Procedures; Outcome; Parents; Patients; Pattern; Persons; Physiology; Postoperative Period; Presbyterian Church; Protocols documentation; Randomized; Randomized Clinical Trials; Recording of previous events; Recovery; Recovery of Function; Recruitment Activity; Research; Risk; Risk Factors; Role; Sample Size; Sampling; Severities; Site; Symptoms; Testing; Texas; Time; Transfusion; Universities; University Hospitals; Virginia; Vulnerable Populations; Walking; Wood material; acute coronary syndrome; cardiovascular disorder risk; cardiovascular risk factor; clinical research site; cognitive function; design; experience; foot; functional outcomes; high risk; improved; instrumental activity of daily living; interest; medical schools; mortality; performance site; prevent; primary outcome; repaired; secondary outcome

DESCRIPTION (provided by applicant): Proposed is an ancillary study to the Transfusion Therapy Trial for Functional Outcomes in Cardiovascular Patients Undergoing Surgical Hip Fracture Repair (FOCUS) to examine the impact of the hemoglobin interventions on delirium in a sub-sample of 200 subjects (100 per randomization group). FOCUS is a randomized clinical trial of 2,000 hip fracture patients funded by the NHLBI designed to test the hypothesis that a higher blood transfusion threshold does not improve functional recovery or reduce morbidity and mortality. Patients are randomized to receive enough blood to maintain hemoglobin level >10 g/dL versus receiving transfusion if hemoglobin level is less than 8 g/dL or when symptoms of anemia develop (symptomatic strategy). This ancillary study will extend our understanding the effects of transfusion thresholds on delirium. The primary aims are to determine whether a symptomatic transfusion strategy (8 g/dL) is associated with more severe symptoms of acute delirium during hospitalization compared to a 10 g/dL transfusion strategy. Secondary aims will examine whether the transfusion randomization also affects persistence of delirium symptoms at 30 days post-discharge and will examine the association of in hospital and 30-day persistence of delirium symptoms on later functional outcomes. The 200 subjects will be recruited from 16 FOCUS sites. FOCUS subjects are hip fracture patients, ages 50+, with a history of CVD or cardiovascular risk factors, and who have a post-operative hemoglobin level less than 10 g/dL within 3 days of surgery. Subjects will be assessed for delirium pre- randomization, for up to 3 days post-randomization (in-hospital), and at 30 days post-randomization. Outcomes include 30- and 60-day morbidity, mortality, lower extremity function, instrumental activities of daily living, and discharge location. Our sample size projections seek to detect medium effects. Generalized Estimation Equations will be used to evaluate the longitudinal patterns between the two groups of 100 hip fracture patients using all measurement time points. Intention to treat principles will be followed in the analyses. Analyses will be done by randomization group, and sensitivity analyses will examine whether there are differences in important confounders between groups and their effects on the analyses. PERFORMANCE SITE(S): University of Maryland Baltimore, Baltimore, MD University of Medicine and Dentistry of New Jersey, New Brunswick, NJ Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA Baltimore Research & Education Foundation, Perry Point, MD Clinical Sites: Robert Wood Johnson Hospital, New Brunswick, NJ London Health Science Center, Toronto, Canada Mayo Clinic, St. Mary's Hospital, Rochester, MI Sunny Brook, Toronto, Canada Johns Hopkins Bayview Medical Center, Baltimore MD Cooper University Hospital, Camden, NJ University of Ottowa, Ottowa, Canada Eastern Virginia Medical School, Norfolk, VA Columbia University Medical Center, New York, NY New York Presbyterian Hospital, New York, NY Cleveland Clinic, Cleveland, OH Lahey Clinic Medical Center, Burlington, MA Emory University, Atlanta, GA Texas Technical, Lubbock, TX Maimondes Medical Center, Brooklyn, NY University of British Columbia, Vancouver, Canada This is an ancillary study to a large clinical trial (R01 HL073958) that looks at different levels of blood transfusion to treat blood loss after hip fracture surgery, in patients who also have cardiovascular disease or cardiovascular risk factors. This ancillary study examines whether transfusion helps prevent short-term (post- randomization) and long-term (30 day) changes in delirium.

描述（由申请方提供）：拟定的是一项对接受髋关节骨折修复术的心血管患者功能结局的输血治疗试验（FOCUS）的辅助研究，旨在检查血红蛋白干预对200例受试者（每个随机分组100例）子样本中谵妄的影响。FOCUS是一项由NHLBI资助的2,000名髋部骨折患者的随机临床试验，旨在验证较高的输血阈值不会改善功能恢复或降低发病率和死亡率的假设。患者随机接受足够的血液以维持血红蛋白水平>10 g/dL，而如果血红蛋白水平低于8 g/dL或出现贫血症状时接受输血（对症策略）。这项辅助研究将扩展我们对输血阈值对谵妄影响的理解。主要目的是确定与10 g/dL输血策略相比，住院期间症状性输血策略（8 g/dL）是否与更严重的急性谵妄症状相关。次要目的将检查输血随机化是否也影响出院后30天谵妄症状的持续性，并将检查住院和谵妄症状持续30天与后期功能结局的相关性。将从16家FOCUS研究中心招募200例受试者。FOCUS受试者是年龄50岁以上、有CVD或心血管风险因素病史、术后3天内血红蛋白水平低于10 g/dL的髋部骨折患者。将在随机化前、随机化后最多3天（住院）和随机化后30天评估受试者的谵妄。结果包括30和60天的发病率，死亡率，下肢功能，工具性日常生活活动，和出院地点。我们的样本量预测试图检测中等效应。将使用广义估计方程评价两组100例髋部骨折患者在所有测量时间点的纵向模式。分析中将遵循意向治疗原则。将按随机分组进行分析，敏感性分析将检查组间重要混杂因素是否存在差异及其对分析的影响。履约地点：马里兰州巴尔的摩大学，巴尔的摩，医学博士新泽西州医学和牙科大学，新玩法，新泽西州贝斯以色列女执事医疗中心，哈佛医学院，波士顿，马萨诸塞州巴尔的摩研究与教育基金会，佩里角，医学博士临床研究中心：罗伯特·伍德约翰逊医院，新玩法，新泽西州伦敦健康科学中心，多伦多，加拿大马约诊所，圣玛丽医院，罗切斯特，密歇根州桑尼布鲁克，多伦多，加拿大约翰霍普金斯湾景医疗中心，巴尔的摩医学博士库珀大学医院，卡姆登，新泽西州奥托瓦大学，奥托瓦，加拿大东弗吉尼亚医学院，诺福克，弗吉尼亚州哥伦比亚大学医学中心，纽约，纽约长老会医院，纽约，纽约克利夫兰诊所，克利夫兰，俄亥俄州莱希诊所医疗中心，伯灵顿，马萨诸塞州埃默里大学，亚特兰大，佐治亚州得克萨斯州技术，拉伯克，TX Maimondes医学中心，布鲁克林，纽约不列颠哥伦比亚省大学，温哥华，加拿大这是一项大型临床试验（R 01 HL 073958）的辅助研究，该试验旨在观察不同水平的输血治疗髋部骨折手术后失血，患者同时患有心血管疾病或心血管风险因素。这项辅助研究检查了输血是否有助于预防谵妄的短期（随机化后）和长期（30天）变化。